Roflumilast enhances cisplatin‐sensitivity and reverses cisplatin‐resistance of ovarian cancer cells via <scp>cAMP</scp>/<scp>PKA</scp>/<scp>CREB</scp>‐FtMt signalling axisShipeng Gong(Nanfang Hospital), Fei Wu(Nanfang Hospital)Cell ProliferationAugust 2, 201810.1111/cpr.12474Cited by 28SaveCiteExport RISWatch citationsRelated PapersRoflumilast restores cAMP/PKA/CREB signaling axis for FtMt-mediated tumor inhibition of ovarian cancer|Oncotarget|2017|45MyoD1 promotes the transcription of BIK and plays an apoptosis-promoting role in the development of gastric cancer|Cell Cycle|2024|6